Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D004967:Estrogens / Q000502:physiology; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D009842:Oligopeptides / Q000627:therapeutic use*; D009919:Orchiectomy; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D013739:Testosterone / Q000097:blood; D017211:Treatment Failure
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004967:Estrogens; D009363:Neoplasm Proteins; D009842:Oligopeptides; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D005640:Follicle Stimulating Hormone; D017430:Prostate-Specific Antigen; C423508:abarelix